PI3K6 Protein: A Promising Drug Target for Various Diseases (G146850)

Target Name: PIK3R6

NCBI ID: G146850

PIK3R6

PI3K6 Protein: A Promising Drug Target for Various Diseases

The PIK3R6 protein, also known as PI3Kgamma adapter protein of 87 kDa, is a protein that is expressed in various cell types throughout the body. It is a key regulator of the phosphatidylinositol (PI) signaling pathway, which is involved in various cellular processes such as cell signaling, migration, and invasion. The PI signaling pathway is a well-established target for drug development, and the PIK3R6 protein is a promising biomarker and potential drug target in various diseases.

The PI signaling pathway is a complex network that involves the interaction of various protein components. The PIK3R6 protein plays a crucial role in this pathway as an adapter protein. It serves as a bridge between the PI3K signaling pathway and the PIK4/Akt signaling pathway, which is a target for many anti-cancer drugs. The PIK3R6 protein functions by interacting with the protein kinase Akt, which is a key component of the PI3K signaling pathway. This interaction allows the PIK3R6 protein to regulate the activity of the PI3K signaling pathway, thereby participating in the regulation of various cellular processes.

The PIK3R6 protein is a 87 kDa protein that is expressed in various cell types, including neurons, endothelial cells, and cancer cells. It is highly conserved, with a calculated pI of 12.95 and a predicted localization in the cytoplasm. The PIK3R6 protein is involved in various cellular processes, including cell signaling, migration, and invasion. It is a potent inhibitor of the Akt protein, which is a key component of the PI3K signaling pathway.

The PIK3R6 protein has been shown to be involved in various diseases, including cancer. For example, studies have shown that the PIK3R6 protein is overexpressed in various types of cancer, such as breast cancer, lung cancer, and colorectal cancer. This overexpression is associated with poor prognosis and decreased therapeutic response to anti-cancer drugs. Additionally, the PIK3R6 protein has been shown to be involved in the regulation of cellular processes that are critical for cancer cell growth and survival, such as cell migration and invasion.

The PIK3R6 protein is also a potential drug target for several diseases. The PIK3R6 protein has been shown to be involved in the regulation of cellular processes that are critical for diseases such as cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, the PIK3R6 protein has has been shown to be involved in the regulation of cellular processes that are critical for the development and progression of diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, the PIK3R6 protein is a key regulator of the PI signaling pathway and has been shown to be involved in various diseases. Its potential as a drug target makes it an attractive target for research and development of new treatments for various diseases. Further studies are needed to fully understand the role of the PIK3R6 protein in disease and to develop effective treatments.

Protein Name: Phosphoinositide-3-kinase Regulatory Subunit 6

Functions: Regulatory subunit of the PI3K gamma complex. Acts as an adapter to drive activation of PIK3CG by beta-gamma G protein dimers. The PIK3CG:PIK3R6 heterodimer is much less sensitive to beta-gamma G protein dimers than PIK3CG:PIK3R5 and its membrane recruitment and beta-gamma G protein dimer-dependent activation requires HRAS bound to PIK3CG. Recruits of the PI3K gamma complex to a PDE3B:RAPGEF3 signaling complex involved in angiogenesis; signaling seems to involve RRAS

The "PIK3R6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIK3R6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets